Evidence map›Paper›PMID 24727746›Full record

ArticlePloS one2014

Critical importance of long-term adherence to care in HIV infected patients in the cART era: new insights from Pneumocystis jirovecii pneumonia cases over 2004-2011 in the FHDH-ANRS CO4 cohort.

Blandine Denis, Marguerite Guiguet, Nathalie de Castro, Frédéric Mechaï, Matthieu Revest, Aba Mahamat, Giovanna Melica Gregoire, Olivier Lortholary, Dominique Costagliola

Abstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. SevereJMM case reports · 2014
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Blandine DenisInserm UMRS 1136, Paris, France; UPMC Univ Paris 06 UMRS 1136, Paris, France.
Marguerite GuiguetInserm UMRS 1136, Paris, France; UPMC Univ Paris 06 UMRS 1136, Paris, France.
Nathalie de CastroService de maladies infectieuses et tropicales, CHU Saint Louis, AP-HP, Paris, France; Université Paris Diderot, Paris, France.
Frédéric MechaïService de maladies infectieuses et tropicales, CHU Avicenne AP-HP, Bobigny, France.
Matthieu RevestService de maladies infectieuses et tropicales, CHU Rennes, Rennes, France.
Aba MahamatService de maladies infectieuses et tropicales, CHU Cayenne, Cayenne, France; EA 3595, Univ Antilles-Guyane, Cayenne, France.
Giovanna Melica GregoireService de maladies infectieuses et tropicales, CHU Saint Louis, AP-HP, Paris, France; Université Paris Diderot, Paris, France.
Olivier LortholaryCHU Necker-Enfants malades, AP-HP, Centre d'Infectiologie Necker Pasteur, Paris, France; Université Paris Descartes, Institut Imagine, Paris, France; Institut Pasteur, Centre National de Référence Mycoses Invasives et Antifongiques, Paris, France; CNRS URA 3012, Paris, France.
Dominique CostagliolaInserm UMRS 1136, Paris, France; UPMC Univ Paris 06 UMRS 1136, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo describe characteristics and outcomes of HIV-infected patients with Pneumocystis jirovecii pneumonia (PCP) over 2004-2011 in France, in particular in those previously enrolled (PE) in the French Hospital Database on HIV (FHDH).

methodsPE patients with an incident PCP were compared with patients with an inaugural PCP revealing HIV infection (reference). Adequate adherence to care was defined as a CD4 measurement at least every 6 months. Immune reconstitution (CD4≥200/mm3) and risk of death were studied using Kaplan-Meier estimates and multivariable Cox proportional hazards models.

resultsIn a context of a decreasing incidence of PCP, 1259 HIV-infected patients had a PCP diagnosis, and 593 (47%) were PE patients of whom 161 (27%) have had a prior history of AIDS-defining clinical illness (prior ADI). Median time since enrolment was 8 years for PE patients; 74% had received cART. Median proportion of time with adequate adherence to care was 85% (IQR, 66-96) for all FHDH enrollees, but only 45% (IQR, 1-81) for PE patients during the 2 years before PCP. Median CD4 cell count (38/mm3) and HIV viral load (5.2 log10 copies/ml) at PCP diagnosis did not differ between PE patients and the reference group. Three year mortality rate of 25% was observed for PE prior ADI group, higher than in PE non-prior ADI group (8%) and the reference group (9%) (p<0.0001). In the PE prior ADI group, poor prognosis remained even after adjustment for virological control and immune reconstitution (HR, 2.4 [95%CI, 1.5-3.7]).

conclusionAlmost 50% of PCP diagnoses in HIV-infected patients occurred presently in patients already in care, mainly with a previous cART prescription but with waning adherence to care. Having repeated ADI is contributing to the risk of death beyond its impact on immune reconstitution and viral suppression: special efforts must be undertaken to maintain those patients in care.

Indexed as

CD4 AntigensHIV InfectionsHumansKaplan-Meier EstimatePatient CompliancePneumocystis cariniiPneumoniaCD4 Antigens

Identifiers

PMID24727746
PMCPMC3984113

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.